Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays
- 13 July 2022
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (1) , 235-247
Abstract
Autoantibody (AAb) has a prominent role in prostate cancer (PCa), with few studies profiling the AAb landscape in Chinese patients. Therefore, the AAb landscape in Chinese patients was characterized using protein arrays. First, in the discovery phase, Huprot arrays outlined autoimmune profiles against ~ 21,888 proteins from 57 samples. In the verification phase, the PCa-focused arrays detected 25 AAbs selected from the discovery phase within 178 samples. Then, PCa was detected using a backpropagation artificial neural network (BPANN) model. In the validation phase, an enzyme-linked immunosorbent assay (ELISA) was used to validate four AAb biomarkers from 196 samples. Huprot arrays profiled distinct PCa, benign prostate diseases (BPD), and health AAb landscapes. PCa-focused array depicted that IFIT5 and CPOX AAbs could distinguish PCa from health with an area under curve (AUC) of 0.71 and 0.70, respectively. PAH and FCER2 AAbs had AUCs of 0.86 and 0.88 in discriminating PCa from BPD. Particularly, PAH AAb detected patients in the prostate-specific antigen (PSA) gray zone with an AUC of 0.86. Meanwhile, the BPANN model of 4-AAb (IFIT5, PAH, FCER2, CPOX) panel attained AUC of 0.83 among the two cohorts for detecting patients with gray-zone PSA. In the validation cohort, the IFIT5 AAb was upregulated in PCa compared to health (p < 0.001). Compared with BPD, PAH and FCER2 AAbs were significantly elevated in PCa (p = 0.012 and 0.039). We have demonstrated the first extensive profiling of autoantibodies in Chinese PCa patients, identifying novel diagnostic AAb biomarkers, especially for identification of gray-zone-PSA patients.Keywords
Funding Information
- Research Special Fund for Public Welfare Industry of Health (201402001)
This publication has 47 references indexed in Scilit:
- DNA methylation presents distinct binding sites for human transcription factorseLife, 2013
- EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assaysTumor Biology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- PhenylketonuriaThe Lancet, 2010
- Clinical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Autoantibodies to tumor‐associated antigens: reporters from the immune systemImmunological Reviews, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Anti-angiogenic activity of inositol hexaphosphate (IP6)Carcinogenesis, 2004
- Humoral Immune Response to -Methylacyl-CoA Racemase and Prostate CancerJNCI: Journal of the National Cancer Institute, 2004
- In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol HexaphosphateClinical Cancer Research, 2004